WO2006105338A3 - Fc VARIANTS WITH OPTIMIZED PROPERTIES - Google Patents

Fc VARIANTS WITH OPTIMIZED PROPERTIES Download PDF

Info

Publication number
WO2006105338A3
WO2006105338A3 PCT/US2006/011752 US2006011752W WO2006105338A3 WO 2006105338 A3 WO2006105338 A3 WO 2006105338A3 US 2006011752 W US2006011752 W US 2006011752W WO 2006105338 A3 WO2006105338 A3 WO 2006105338A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
optimized properties
optimized
properties
methods
Prior art date
Application number
PCT/US2006/011752
Other languages
French (fr)
Other versions
WO2006105338A2 (en
Inventor
Gregory Alan Lazar
Wei Dang
John R Desjarlais
Sher Bahadur Karki
Original Assignee
Xencor Inc
Gregory Alan Lazar
Wei Dang
John R Desjarlais
Sher Bahadur Karki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/124,620 external-priority patent/US8188231B2/en
Application filed by Xencor Inc, Gregory Alan Lazar, Wei Dang, John R Desjarlais, Sher Bahadur Karki filed Critical Xencor Inc
Priority to AU2006230413A priority Critical patent/AU2006230413B8/en
Priority to JP2008504389A priority patent/JP2008537941A/en
Priority to CA002602663A priority patent/CA2602663A1/en
Priority to EP06748967A priority patent/EP1871808A2/en
Publication of WO2006105338A2 publication Critical patent/WO2006105338A2/en
Publication of WO2006105338A3 publication Critical patent/WO2006105338A3/en
Priority to IL186145A priority patent/IL186145A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to Fc variants with optimized properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized properties, and methods for using Fc variants with optimized properties.
PCT/US2006/011752 2005-03-31 2006-03-31 Fc VARIANTS WITH OPTIMIZED PROPERTIES WO2006105338A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2006230413A AU2006230413B8 (en) 2005-03-31 2006-03-31 Fc variants with optimized properties
JP2008504389A JP2008537941A (en) 2005-03-31 2006-03-31 Fc variants with optimized properties
CA002602663A CA2602663A1 (en) 2005-03-31 2006-03-31 Fc variants with optimized properties
EP06748967A EP1871808A2 (en) 2005-03-31 2006-03-31 Fc VARIANTS WITH OPTIMIZED PROPERTIES
IL186145A IL186145A0 (en) 2005-03-31 2007-09-20 Fc VARIANTS WITH OPTIMIZED PROPERTIES

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US66719705P 2005-03-31 2005-03-31
US60/667,197 2005-03-31
US11/124,620 US8188231B2 (en) 2002-09-27 2005-05-05 Optimized FC variants
US11/124,620 2005-05-05
US70537805P 2005-08-03 2005-08-03
US60/705,378 2005-08-03
US72329405P 2005-10-03 2005-10-03
US72333505P 2005-10-03 2005-10-03
US60/723,294 2005-10-03
US60/723,335 2005-10-03

Publications (2)

Publication Number Publication Date
WO2006105338A2 WO2006105338A2 (en) 2006-10-05
WO2006105338A3 true WO2006105338A3 (en) 2007-03-29

Family

ID=37054149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/011752 WO2006105338A2 (en) 2005-03-31 2006-03-31 Fc VARIANTS WITH OPTIMIZED PROPERTIES

Country Status (5)

Country Link
EP (1) EP1871808A2 (en)
AU (1) AU2006230413B8 (en)
CA (1) CA2602663A1 (en)
IL (1) IL186145A0 (en)
WO (1) WO2006105338A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8158760B2 (en) 2000-10-06 2012-04-17 Kyowa Hakko Kirin Co., Ltd Glycoengineered, recombinant antibody
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2571230T3 (en) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure to control the activity of an immunofunctional molecule
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
CN103351434B (en) * 2004-07-15 2015-09-30 赞科股份有限公司 The Fc variant optimized
PL1776384T3 (en) 2004-08-04 2013-10-31 Mentrik Biotech Llc Variant fc regions
AU2006268227A1 (en) * 2005-07-08 2007-01-18 Xencor, Inc Optimized anti-Ep-CAM antibodies
WO2007041635A2 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CN105177091A (en) 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody
JP5624276B2 (en) 2006-03-31 2014-11-12 中外製薬株式会社 Methods for controlling blood kinetics of antibodies
WO2008010101A2 (en) 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody against epha2 for the treatment of cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2008121160A2 (en) * 2006-11-21 2008-10-09 Xencor, Inc. Optimized antibodies that target cd5
AR063975A1 (en) 2006-11-28 2009-03-04 Centelion FC FUSIONS WITH RECEIVER FOR FGF SOLUBLE MODIFIED WITH IMPROVED BIOLOGICAL ACTIVITY
WO2008091798A2 (en) * 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
CA2669412A1 (en) * 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
CA2676529C (en) 2007-01-24 2014-03-25 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition having enhanced effector activity
WO2008092117A2 (en) * 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
WO2008098115A2 (en) * 2007-02-07 2008-08-14 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
CA2689680C (en) 2007-05-14 2017-11-07 Novimmune Sa Fc receptor-binding polypeptides with modified effector functions
WO2008150494A1 (en) * 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
BRPI0814471A2 (en) * 2007-08-01 2015-02-03 Glaxo Group Ltd ANTIBODY PREPARATION, METHOD FOR PRODUCING ANTIBODY PREPARATION, PHARMACEUTICAL COMPOSITION, PARTS KIT, AND USING AN ANTIBODY PREPARATION
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
WO2009086320A1 (en) 2007-12-26 2009-07-09 Xencor, Inc Fc variants with altered binding to fcrn
MY195714A (en) 2008-04-11 2023-02-07 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly
US8314213B2 (en) 2008-04-18 2012-11-20 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
EP2426149A4 (en) 2009-05-01 2013-01-23 Univ Tokyo Anti-cadherin antibody
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
UY32914A (en) 2009-10-02 2011-04-29 Sanofi Aventis ANTIBODIES SPECIFICALLY USED TO THE EPHA2 RECEIVER
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
AR080154A1 (en) 2010-02-10 2012-03-14 Immunogen Inc CD20 ANTIBODIES AND ITS USE
EP2848632B1 (en) 2010-02-23 2019-07-10 Sanofi Human igg1 fc with improved cdc and adcc activity
AU2011222012C1 (en) 2010-03-02 2015-02-26 Kyowa Kirin Co., Ltd. Modified antibody composition
TWI667257B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
MX339809B (en) 2010-05-27 2016-06-09 Merck Sharp & Dohme Corp * Method for preparing antibodies having improved properties.
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
AU2011299066A1 (en) 2010-09-10 2013-03-21 Apexigen, Inc. Anti-IL-1 beta antibodies and methods of use
ES2693232T3 (en) 2010-11-30 2018-12-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent that induces cytotoxicity
KR102385507B1 (en) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
CA2827581A1 (en) 2011-03-03 2012-09-07 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
JP5832559B2 (en) 2011-03-10 2015-12-16 オメロス コーポレーション Generation of anti-FN14 monoclonal antibodies by accelerated antibody evolution ex vivo
DK2698431T3 (en) 2011-03-30 2020-11-30 Chugai Pharmaceutical Co Ltd Maintenance of antigen-binding molecules in blood plasma and method of modifying immunogenicity
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
JP5944994B2 (en) 2011-08-12 2016-07-05 オメロス コーポレーション Anti-FZD10 monoclonal antibodies and methods for their use
UY34317A (en) 2011-09-12 2013-02-28 Genzyme Corp T cell antireceptor antibody (alpha) / ß
CN107287660A (en) 2011-09-30 2017-10-24 中外制药株式会社 Ion concentration dependence binding molecule library
CN104093424A (en) 2011-09-30 2014-10-08 中外制药株式会社 Antigen-binding molecule inducing immune response to target antigen
TW201326209A (en) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
TWI812924B (en) 2011-09-30 2023-08-21 日商中外製藥股份有限公司 Antigen-binding molecules that promote antigen disappearance
WO2013047748A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
WO2013067098A1 (en) 2011-11-02 2013-05-10 Apexigen, Inc. Anti-kdr antibodies and methods of use
RU2739792C1 (en) 2011-11-30 2020-12-28 Чугаи Сейяку Кабусики Кайся Carrier containing a drug into a cell for forming an immune complex
WO2013087789A1 (en) * 2011-12-13 2013-06-20 Glykos Finland Ltd. Antibody isoform arrays and methods thereof
EP3539982A3 (en) 2011-12-23 2020-01-15 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TWI593705B (en) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
SG11201405137QA (en) 2012-02-24 2014-12-30 Chugai Pharmaceutical Co Ltd ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB
US9751942B2 (en) 2012-03-29 2017-09-05 Chugai Seiyaku Kabushiki Kaisha Anti-LAMP5 antibody and utilization thereof
ES2856272T3 (en) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule to remove aggregated antigens
TWI766939B (en) 2012-05-30 2022-06-11 日商中外製藥股份有限公司 target tissue-specific antigen binding molecule
KR102273985B1 (en) 2012-08-24 2021-07-06 추가이 세이야쿠 가부시키가이샤 FcγRIIb-specific Fc region variant
WO2014030750A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 MOUSE FcγRII-SPECIFIC Fc ANTIBODY
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
CA2889681C (en) 2012-09-27 2023-04-11 Merus B.V. Bispecific igg antibodies as t cell engagers
CN110066335B (en) 2012-10-30 2024-04-05 埃派斯进有限公司 anti-CD 40 antibodies and methods of use thereof
CN105026426A (en) 2012-11-09 2015-11-04 辉瑞公司 Platelet-derived growth factor b specific antibodies and compositions and uses thereof
TWI693073B (en) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients
EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
RU2711935C2 (en) 2013-03-11 2020-01-23 Джензим Корпорейшн Site-specific antibody-drug conjugation by means of glycoengineering
CN113621057A (en) 2013-04-02 2021-11-09 中外制药株式会社 Fc region variants
WO2014190441A1 (en) 2013-05-31 2014-12-04 Zymeworks Inc. Heteromultimers with reduced or silenced effector function
EP3015115A4 (en) 2013-06-24 2017-02-22 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
SG11201602261VA (en) 2013-09-27 2016-04-28 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
AU2014348552A1 (en) 2013-11-13 2016-06-02 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
JP6740126B2 (en) 2013-11-13 2020-08-12 ファイザー・インコーポレイテッド Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
RU2737882C2 (en) 2013-11-27 2020-12-04 Займворкс Инк. Bispecific antigen-binding constructs against her2
TW202043467A (en) 2013-12-04 2020-12-01 日商中外製藥股份有限公司 Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CA2942769A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
ES2900898T3 (en) 2014-04-07 2022-03-18 Chugai Pharmaceutical Co Ltd Bispecific immunoactivating antibodies
CN106459959A (en) 2014-05-08 2017-02-22 中外制药株式会社 GPC3-targeted therapeutic agent for administration to patients for whom GPC3-targeted therapeutic agent therapy is effective
WO2015174439A1 (en) 2014-05-13 2015-11-19 中外製薬株式会社 T cell-redirected antigen-binding molecule for cells having immunosuppression function
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
CN108025083B (en) 2014-10-09 2021-09-03 建新公司 Glycoengineered antibody drug conjugates
EP3223848A4 (en) 2014-11-27 2018-07-18 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
MA41294A (en) 2014-12-19 2017-11-08 Chugai Pharmaceutical Co Ltd ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING FC REGION VARIANTS, AND METHODS OF USE
EP3253778A1 (en) 2015-02-05 2017-12-13 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
AR104368A1 (en) 2015-04-03 2017-07-19 Lilly Co Eli ANTI-CD20- / ANTI-BAFF BIESPECTIFIC ANTIBODIES
EP3292143B1 (en) 2015-05-04 2019-08-21 Apogenix AG Single-chain cd40-receptor agonist proteins
JP7010811B2 (en) 2015-07-10 2022-02-10 メルス ナムローゼ フェンノートシャップ Human CD3 binding antibody
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
CR20180217A (en) 2015-09-18 2018-05-03 Chugai Pharmaceutical Co Ltd ANTIBODIES THAT JOIN INTERLEUCINE 8 (IL-8) AND ITS USES
TW201722989A (en) 2015-10-23 2017-07-01 輝瑞大藥廠 Anti-IL-2 antibodies and compositions and uses thereof
WO2017086367A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
JP6925278B2 (en) 2015-11-18 2021-08-25 中外製薬株式会社 Method of enhancing humoral immune response
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
MX2018010988A (en) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy.
ES2904286T3 (en) 2016-03-15 2022-04-04 Chugai Pharmaceutical Co Ltd Cancer Treatment Methods Using PD-1 Axis Binding Antagonists and Anti-GPC3 Antibodies
MA45328A (en) * 2016-04-01 2019-02-06 Avidity Biosciences Llc NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
DK3468997T3 (en) 2016-06-08 2023-10-02 Xencor Inc Treatment of IgG4-related diseases with anti-CD9 antibodies cross-linked to CD32B
AU2017305073B2 (en) 2016-08-05 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Composition for prevention or treatment of IL-8 related diseases
US10870694B2 (en) 2016-09-02 2020-12-22 Dana Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CA3036564A1 (en) * 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
SG11201907288RA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Cysteine mutated antibodies for conjugation
AU2018244574A1 (en) * 2017-03-28 2019-10-31 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
CN116271012A (en) 2017-07-27 2023-06-23 瑞颂医药公司 High concentration anti-C5 antibody formulations
US20200216542A1 (en) 2017-09-20 2020-07-09 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
WO2019090002A1 (en) * 2017-11-02 2019-05-09 Systimmune, Inc. Bispecific antibodies and methods of making and using thereof
EP3732201A4 (en) 2017-12-19 2022-04-20 Surrozen Operating, Inc. Wnt surrogate molecules and uses thereof
CA3085785A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
EP3740509A4 (en) 2018-01-17 2022-06-22 Apexigen, Inc. Anti-pd-l1 antibodies and methods of use
EP3765525B1 (en) 2018-03-13 2023-07-19 Zymeworks BC Inc. Anti-her2 biparatopic antibody-drug conjugates and methods of use
KR20200132938A (en) 2018-03-15 2020-11-25 추가이 세이야쿠 가부시키가이샤 Anti-dengue virus antibodies with cross-reactivity against Zika virus and methods of use
KR20210029158A (en) 2018-06-03 2021-03-15 람카프 바이오 베타 엘티디. Bispecific antibodies to CEACAM5 and CD47
WO2019244107A1 (en) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US20220153875A1 (en) 2019-03-19 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
TW202102544A (en) * 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 Bispecific antibody
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
WO2021122733A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
KR20230121772A (en) 2020-12-18 2023-08-21 람카프 바이오 베타 엘티디. Bispecific antibodies to CEACAM5 and CD47
CA3221735A1 (en) 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051642A1 (en) * 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
WO2000042072A2 (en) * 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
US20020004587A1 (en) * 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
WO2004063351A2 (en) * 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2004099249A2 (en) * 2003-05-02 2004-11-18 Xencor, Inc. Optimized fc variants and methods for their generation
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
WO2005070963A1 (en) * 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Fc region variants
WO2005092925A2 (en) * 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2006019447A1 (en) * 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
WO2006047350A2 (en) * 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2006053301A2 (en) * 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051642A1 (en) * 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
WO2000042072A2 (en) * 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
US20020004587A1 (en) * 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
WO2004063351A2 (en) * 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2004099249A2 (en) * 2003-05-02 2004-11-18 Xencor, Inc. Optimized fc variants and methods for their generation
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2005070963A1 (en) * 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Fc region variants
WO2005092925A2 (en) * 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
WO2006019447A1 (en) * 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
WO2006047350A2 (en) * 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2006053301A2 (en) * 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 394A, ISSN: 0006-4971 *
CHAPPEL M S ET AL: "Identification of a secondary FcyRI binding site within a genetically engineered human IgG antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 268, no. 33, 1993, pages 25124 - 25131, XP002337952, ISSN: 0021-9258 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2004 (2004-11-01), LAZAR GREG ET AL: "Improving the efficacy of rituxan by rational protein engineering.", XP002403709, Database accession no. PREV200510269378 *
LAZAR GREG A ET AL: "Engineered antibody Fc variants with enhanced effector function", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 103, no. 11, March 2006 (2006-03-01), pages 4005 - 4010, XP002403708, ISSN: 0027-8424 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158760B2 (en) 2000-10-06 2012-04-17 Kyowa Hakko Kirin Co., Ltd Glycoengineered, recombinant antibody
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain

Also Published As

Publication number Publication date
IL186145A0 (en) 2008-01-20
AU2006230413B2 (en) 2010-09-23
AU2006230413B8 (en) 2011-01-20
EP1871808A2 (en) 2008-01-02
AU2006230413A1 (en) 2006-10-05
CA2602663A1 (en) 2006-10-05
WO2006105338A2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
WO2006104989A3 (en) Altered antibody fc regions and uses thereof
WO2007014930A3 (en) Polyammonium/polysiloxane copolymers
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2009070243A3 (en) Wise binding antibodies and epitopes
EG25348A (en) Process for the manufacture of diesel range hydrocarbons.
WO2009039307A3 (en) Hydrogels and methods for producing and using the same
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2007060117A3 (en) Chimeric keratin-binding effector proteins
PL2468732T3 (en) 1H-Quinazoline-2,4-diones
WO2007112279A3 (en) Resonators
WO2007057018A3 (en) Glucoamylase variants
WO2007127506A3 (en) Anti-ephrinb2 antibodies and methods using same
WO2007056083A3 (en) Biosynthetic polypeptide fusion inhibitors
ZA200500854B (en) Wine making system.
EP1929207A4 (en) Multi-mode lighter
WO2007002096A3 (en) Methods and compositions for targeting ifnar2
WO2007127830A3 (en) Dep2 and its uses in major depressive disorder and other related disorders
AU2005901102A0 (en) The I.D. charm
AU2006906675A0 (en) The multiscooper.
AU2005906280A0 (en) Budgetchoice.com
AU2005900030A0 (en) Glowbal, Glowves, Moonstik
GB0510175D0 (en) New polypeptide, uses thereof and methods employing it

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006748967

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1452/MUMNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 186145

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006230413

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2602663

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008504389

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006230413

Country of ref document: AU

Date of ref document: 20060330

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application